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Abstract A peptide fragment derived from the p41 form of the 
invariant chain (Ii) associated with the major histocompatibility 
complex (MHC) class II molecule has been shown to inhibit the 
mammalian lysosomal cysteine proteinase, cathepsin L, and to be 
a novel cysteine proteinase inhibitor, distinct from cystatins. 
Here we report that this same fragment also binds to and inhibits 
cruzipain, the cathepsin L-like enzyme from the protozoan 
parasite Trypanosoma cruzi. The binding of the Ii fragment 
to cruzipain is fast (kass = 2.4 X10
7 M"1 s"1) and tight 
(Ki = 5.8 X10 n M). The inhibition is competitive. These results 
suggest the possibility of using the invariant chain as a model for 
the specific inhibition of cruzipain in vivo, i.e. as a potential drug 
to combat Chagas' disease. 
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1. Introduction 
Cruzipain is the major cysteine proteinase of Trypanosoma 
cruzi, the parasitic flagellate which is the causative agent of 
American trypanosomiasis, Chagas' disease [1]. It is a lysoso-
mal enzyme [2], also found at the cell surface of the parasite 
[3]. The mature enzyme consists of a catalytic domain homol-
ogous to cysteine proteinases from the papain family [4,5], 
and an unusual C-terminal extension, also present in related 
enzymes of other trypanosomatids [6]. The enzyme has been 
expressed in E. coli, and by self-processing of the precursor, 
active enzyme lacking the C-terminal extension (also called 
cruzain) was obtained [5] and crystallised [7]. The three-di-
mensional structure of the enzyme complexed with the irre-
versible inhibitor Z-Phe-Ala-fiuoromethylketone has been 
solved, revealing that cruzipain is isostructural with papain 
[8] and suggesting a common catalytic mechanism [9]. 
Cruzipain is inhibited by a range of organomercurial, 
epoxysuccinyl and peptide aldehyde compounds [10,11], as 
well as by protein inhibitors belonging to the cystatin super-
family [12,13]. The latter bind tightly to the enzyme with K\ 
values between 1 and 72 pM [12]. 
The invariant chain (Ii) is an integral membrane protein 
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which is associated with the major histocompatibility complex 
(MHC) class II heterodimer during early stages of its intra-
cellular transport. It contributes critically to a proper presen-
tation of antigens to CD4+ T lymphocytes [14]. Recently, a 
novel property of Ii has been established. A 65 amino acid 
fragment from Ii exhibits strong inhibitory activity against 
cathepsin L (Äj = 1.7 pM), and also inhibits moderately 
cathepsin H ( ^ = 5.3 nM) and papain (^i=1.4 nM) [15]. It 
corresponds to the alternatively spliced fragment, which is 
present only in the minor, p41, but not in the major, p31, 
form of Ii. The inhibitory fragment shows no sequence homol-
ogy to known cysteine proteinase inhibitors from the cystatin 
superfamily, and therefore represents a new class of inhibitors. 
In this work we show that cruzipain is also inhibited by the 
alternatively spliced Ii fragment. The kinetics of this inhibition 
were studied in order to characterise the interaction between 
the parasitic proteinase and this new type of cysteine protein-
ase inhibitor. 
2. Materials and methods 
2.1. Materials 
Cruzipain was purified as reported [12]. The Ii fragment, isolated as 
a complex with cathepsin L, was separated using reversed-phase 
HPLC [16], freeze-dried on a Speed-vac concentrator (model RC 
100, Savant Instruments, Farmingdale, USA), and redissolved in dis-
tilled water. 
Protein concentrations were determined according to the method of 
Lowry et al. [17]. 
The concentration of active cruzipain was determined using the 
cysteine proteinase inhibitor Ep-475, and the Ii fragment was titrated 
with active-site-titrated cathepsin L as previously described [15]. 
Ep-475 was purchased from Peptide Research Institute (Osaka, Ja-
pan), and Z-Phe-Arg-MCA from Serva (Heidelberg, Germany). Stock 
solution of the substrate was 1 mM Z-Phe-Arg-MCA in dimethylsulf-
oxide. 
2.2. Determination of rate and equilibrium constants for the inhibition 
of cruzipain by the Ii fragment 
The reaction mixture contained Ii fragment and substrate (Z-Phe-
Arg-MCA) in 0.1 M phosphate buffer, pH 6.5, containing 1 mM 
EDTA. The reaction was started by the addition of 50 μΐ of cruzipain 
(preactivated with 8 mM DTE) to 1.950 ml of the reaction mixture. 
Final concentrations of the substrate and cruzipain were 5 μΜ and 
200 pM, respectively, and the Ii fragment concentration varied from 
2 to 5 nM. All the experiments were carried out at 24°C under pseu-
do-first-order conditions, with at least a 10-fold molar excess of the Ii 
fragment over cruzipain. Less than 5% of substrate was hydrolysed 
during each experiment. The release of product was monitored con-
tinuously at excitation and emission wavelengths of 370 and 460 nm, 
respectively, using a Perkin Elmer LS-50B spectrofluorimeter. 
2.3. Determination of type of inhibition 
The measurements were made under the same experimental condi-
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tions as described in Section 2.2 with a constant final concentration of 
cruzipain (80 pM) and of the Ii fragment (2 nM). The substrate con-
centration was varied from 0.25 to 1.25 μΜ. 
3. Results 
Under the experimental conditions used, all progress curves 
for the interaction between cruzipain and the Ii fragment 
showed an exponentially decreasing release of product with 
time (Fig. 1), following typical biphasic, slow-binding kinetics 
[18]. They were fitted by non-linear least-squares analysis to 
the following integrated rate equation [18]: 
[Ρ] = ν + ( ν ζ - ν 8 ) ( 1 - < Γ
ω ) / Α ; ( (1) 
where [P] is the product concentration, and vz and vs are the 
initial and steady-state velocities, respectively. fc0bS is the ap-
parent pseudo-first-order rate constant describing the pre-
steady-state of enzyme-inhibitor interaction, and is given by 
Eq. 2: 
kobs = W W O + [S0]/Km (2) 
where [I0] and [S0] represent inhibitor and substrate concen-
trations, Km is the Michaelis-Menten constant, fcass the sec-
ond-order rate constant for enzyme-inhibitor complex forma-
tion, and kdiss the rate constant for its dissociation: 
E + El 
fcobs increased linearly with increasing concentration of the 
inhibitor, when substrate and enzyme concentrations were 
kept constant (Fig. 2). A &ass value of (2.4 ± 0.14) X10
7 
M - 1 s - 1 was calculated from the slope of the plot k0\,s vs. 
[I0] [18] using a Km value of 0.27 μΜ [12]. The dissociation 
rate constant kn^ was calculated for each inhibitor concentra-
tion using the following equation [18]: 
kdiSS = kohsXvs/vz (3) 
leading to an average value of (1.4±0.27)X 10 3 s J. The 
from equilibrium inhibition constant K\ was calculated 
Ki = W * . » , giving Ki = (5.8 ± 1.4) X 10"11 M. 
In a control experiment with no inhibitor added, product 
formation was linear, verifying that the enzyme was stable 
during the experiment (Fig. 1). 
The interaction of cruzipain and inhibitor was also investi-
gated at different substrate concentrations with constant con-
centrations of enzyme and inhibitor. The k0bs value showed a 
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Fig. 1. Typical progress curves for the inhibition of cruzipain with 
the Ii fragment. [Eo] = 200 pM, [S„] = 5 μΜ; [Ιο] = 0 (i), [I0] = 2 nM 
(ii), [I0] = 3 nM (iii). Solid lines are theoretical curve fits (Eq. 1). 
linear dependence on l/(l+[So]AKm) (Fig. 3), which indicates a 
competitive inhibition mechanism: 
E ■ 
+ 
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4. Discussion 
Our experimental results show that the p41 invariant chain 
fragment is a potent inhibitor of cruzipain, the major cysteine 
proteinase from T. cruzi. The kinetic behaviour of these two 
molecules is consistent with a reversible, tight-binding inhibi-
tion mechanism [18]. The kinetic constants are of the same 
order of magnitude as those reported for the inhibition of 
cruzipain with cysteine proteinase inhibitors from the cystatin 
superfamily (Table 1), which also bind to cruzipain tightly 
with Ki values in the picomolar range [12]. 
On the other hand, the interaction between cruzipain and 
the Ii fragment is also similar to that of the same Ii fragment 
with cathepsin L [15]. The association rate constants for the 
interaction of cathepsin L and cruzipain with the Ii peptide 
are very similar, whereas the dissociation rate constant was 
considerably lower for cathepsin L (Table 1). The fact that 
cruzipain is inhibited to about the same extent as cathepsin L, 
whereas related enzymes are inhibited only weekly or not at 
Table 1 
Kinetic data for the interactions of cruzipain and of the Ii fragment 
Enzyme Inhibitor ^ ( x l O - ^ C M - 1 s"1) ^ ( x l O 5 ) ^ " 1 ) Ki (pM) 
Cruzipain 
Cathepsin La 
Cruzipainb 
Cruzipainb 
Cruzipainb 
Cruzipainb 
Ii fragment 
Ii fragment 
stefin A 
stefin B 
cystatin C 
L-kininogen 
2.4 ±0.1 
4.6 ±0.1 
0.34 ±0.02 
3.00 ±0.02 
7.90 ±0.05 
1.80±0.01 
140 ±27 
7.7 ±1.0 
25 ±3 
180 ±2 
100 ±2 
74 ±8 
58 ±14 
1.7±0.3 
72.0 ±1.2 
60.0 ±1.0 
14.0 ±0.4 
41.0±0.8 
"From [15]. 
bFrom [12]. 
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Fig. 2. Dependence of the apparent pseudo-flrst-order rate constant 
A:0bS on inhibitor concentration for the interaction between cruzipain 
and the li fragment. [E0] = 200 pM, [S0] = 5 μΜ. The solid line was 
calculated by linear regression analysis. 
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Fig. 3. Dependence of the apparent pseudo-first-order rate constant 
A:0bs on substrate concentration for the interaction between cruzipain 
and the li fragment. [Eo] = 80 pM, [I0] = 2 nM. The solid line was 
calculated by linear regression analysis. 
all [15], is in agreement with previous observations [11,13] that 
the active site geometry of cruzipain resembles mostly cathep-
sin L. 
The inhibitory li fragment shows no sequence homology 
with cystatins, but is homologous to thyroglobulin type-1 do-
main [19]. Recently, a protein from eggs of chum salmon has 
been isolated [20], which shares a high degree of homology 
with the thyroglobulin type-1 motif, and also inhibits cysteine 
proteinases. A novel class of cysteine proteinase inhibitors, 
distinct from cystatins, which had long been known as the 
only protein inhibitors of papain-like cysteine proteinases 
[21], is therefore emerging. The data presented here, together 
with the two other reports on these inhibitors [15,20] provide 
the starting point for building a model of their interaction 
with the target enzymes. The li fragment inhibits cruzipain 
in a competitive manner, which means that, like cystatins, it 
binds to the active site of cruzipain (Fig. 3). 
At present, it is not possible to determine whether cruzipain 
inhibition by the li fragment could occur in vivo. One of the 
steps in the T. cruzi life cycle is penetration of the infective 
trypomastigotes into human macrophages. It could be that 
cruzipain and the p41 form of li (or a peptide derived from 
it) meet within the endosomal pathway of macrophages, 
which are known to be Ii-positive cells. In this case, the K\ 
value is sufficiently low to ensure complex formation at the 
expected physiological concentrations of enzyme and peptide. 
Since cruzipain is a major cysteine proteinase from T. cruzi, 
substances which inhibit it might be useful as models in drug 
design for blocking the T. cruzi life cycle and thus providing a 
cure for Chagas ' disease. The li fragment seems appropriate 
for this task because it shows higher specificity in its action 
compared to inhibitors from cystatin superfamily. 
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